DOCETAXEL VERSUS DOCETAXEL PLUS CAPECITABINE AS NEOADJUVANT CHEMOTHERAPY FOR TRIPLE-NEGATIVE BREAST CANCER PATIENTS

RAA KHAN; AI MASOOD; S KHAN; A MASOOD; . ABDULMANAN; A ZULFIQAR

doi:10.54112/bcsrj.v2024i1.654

Authors

RAA KHAN Department of Radiotherapy, Nishtar Hospital Multan, Pakistan
AI MASOOD Department of Radiotherapy, Nishtar Hospital Multan, Pakistan
S KHAN Department of Radiotherapy, Nishtar Hospital Multan, Pakistan
A MASOOD Department of Radiotherapy, Nishtar Hospital Multan, Pakistan
. ABDULMANAN Department of Radiotherapy, Nishtar Hospital Multan, Pakistan
A ZULFIQAR Department of Radiotherapy, Nishtar Hospital Multan, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.654

Keywords:

Triple Negative Breast Neoplasms, Neoadjuvant Therapy, Docetaxel, Capecitabine, Pathological Complete Response

Abstract

Triple-negative breast cancer (TNBC) poses a significant risk of metastasis and relapse, demanding effective neoadjuvant chemotherapy strategies. This retrospective study aimed to compare the outcomes of a sole docetaxel versus a docetaxel and capecitabine combination (TX) regimen as a neoadjuvant treatment for triple-negative breast cancer. The current retrospective analysis was conducted at the oncology department of Nishtar Hospital Multan and encompassed 80 randomly assigned female patients with triple-negative breast cancer between September 17, 2021, and December 31, 2022. They were further divided into two groups. The TX regimen (docetaxel 75 mg/m2 d1 with capecitabine 800 mg/m2 twice d1-14, q3w) was given to forty patients in the first group named the TX group, where the T regimen (docetaxel 75 mg/m2 d1 q3w) was given to other forty patients assigned in the second group called as T group, over four cycles. The primary endpoint was achieving a pathological complete response (pCR) in the breast, with secondary objectives including pCR in both the breast and axilla, invasive disease-free survival (iDFS), overall 0ne year survival (OS), and safety assessments. In the retrospective analysis, 21 patients in the TX group and 5 in the T group achieved pCR (52.5% vs. 12.5%, p=0.014), demonstrating a statistically significant superiority of the TX regimen. The TX regimen substantially increased pCR incidence (95% CI 2.3-47.1%; p = 0.028) within a subgroup characterized by a high Ki-67 level. The TX group showed a higher incidence of hand-foot syndrome and a statistically insignificant (p > 0.05) incidence of alopecia, presenting a manageable toxicity profile. Comparable iDFS and OS rates were observed in both groups throughout the 12-month average follow-up period. This retrospective analysis indicates that the TX regimen yielded significantly superior results, with a marked increase in pCR rates, particularly in the high Ki-67 subgroup. The observed toxicity profile was manageable, emphasizing the clinical benefits of incorporating capecitabine with docetaxel in neoadjuvant chemotherapy for triple-negative breast cancer patients.

Downloads

Download data is not yet available.

References

Andreetta, C., Puppin, C., Minisini, A., Valent, F., Pegolo, E., Damante, G., Di Loreto, C., Pizzolitto, S., Pandolfi, M., and Fasola, G. (2009). Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer. Annals of Oncology 20, 265-271.

Carvalho, F. M. (2023). Triple-negative breast cancer: from none to multiple therapeutic targets in two decades. Frontiers in Oncology 13, 1244781.

Chan, S., Romieu, G., Huober, J., Delozier, T., Tubiana-Hulin, M., Schneeweiss, A., Lluch, A., Llombart, A., du Bois, A., and Kreienberg, R. (2009). Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. Journal of Clinical Oncology 27, 1753-1760.

Chen, R., Ye, Y., Yang, C., Peng, Y., Zong, B., Qu, F., Tang, Z., Wang, Y., Su, X., and Li, H. (2018). Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients. Breast cancer research and treatment 170, 35-43.

Fabbri, F., Salvi, S., and Bravaccini, S. (2020). Know your enemy: genetics, aging, exposome, and inflammation in the war against triple-negative breast cancer. In "Seminars in Cancer Biology", Vol. 60, pp. 285-293. Elsevier.

Geyer, C., Sikov, W., Huober, J., Rugo, H., Wolmark, N., O’Shaughnessy, J., Maag, D., Untch, M., Golshan, M., and Lorenzo, J. P. (2022). Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of Oncology 33, 384-394.

Gonçalves, A., Bertucci, A., and Bertucci, F. (2020). PARP inhibitors in the treatment of early breast cancer: the step beyond? Cancers 12, 1378.

Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., and Winston, J. S. (2020). Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies. Cancers 12, 2392.

Hong, K., Yao, L., Sheng, X., Ye, D., and Guo, Y. (2021). Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2− Breast Cancer: A Systematic Review and Meta-Analysis. Oncology Research and Treatment 44, 557-567.

Joensuu, H., Kellokumpu-Lehtinen, P.-L., Huovinen, R., Jukkola-Vuorinen, A., Tanner, M., Kokko, R., Ahlgren, J., Auvinen, P., Lahdenperä, O., and Kosonen, S. (2017). Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. Jama Oncology 3, 793-800.

Jones, R. L., Salter, J., A’Hern, R., Nerurkar, A., Parton, M., Reis-Filho, J. S., Smith, I. E., and Dowsett, M. (2009). The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast cancer research and treatment 116, 53-68.

Kitabatake, T., Kojima, K., Fukasawa, M., Beppu, T., and Futagawa, S. (2002). Correlation of thymidine phosphorylase staining and the Ki-67 labeling index to clinicopathologic factors and hepatic metastasis in patients with colorectal cancer. Surgery today 32, 322-328.

Lee, K. S., Ro, J., Nam, B.-H., Lee, E. S., Kwon, Y., Kwon, H. S., Chung, K. W., Kang, H. S., Kim, E. A., and Kim, S. W. (2008). A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast cancer research and treatment 109, 481-489.

Li, J., Yu, K., Pang, D., Wang, C., Jiang, J., Yang, S., Liu, Y., Fu, P., Sheng, Y., and Zhang, G. (2020). Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase III trial. Journal of Clinical Oncology 38, 1774.

Li, Q., Jiang, Y., Wei, W., Yang, H., and Liu, J. (2013). Clinical efficacy of including capecitabine in neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis of randomized controlled trials. PloS one 8, e53403.

Lluch, A., Barrios, C. H., Torrecillas, L., Ruiz-Borrego, M., Bines, J., Segalla, J., Guerrero-Zotano, Á., García-Sáenz, J. A., Torres, R., and de la Haba, J. (2020). Phase III trial of adjuvant capecitabine after standard neo-/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM/2003-11_CIBOMA/2004-01). Journal of clinical oncology 38, 203.

Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., and Kim, S.-B. (2017). Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New England Journal of Medicine 376, 2147-2159.

Medina, M. A., Oza, G., Sharma, A., Arriaga, L., Hernández Hernández, J. M., Rotello, V. M., and Ramirez, J. T. (2020). Triple-negative breast cancer: a review of conventional and advanced therapeutic strategies. International journal of environmental research and public health 17, 2078.

Muss, H. B., Polley, M.-Y. C., Berry, D. A., Liu, H., Cirrincione, C. T., Theodoulou, M., Mauer, A. M., Kornblith, A. B., Partridge, A. H., and Dressler, L. G. (2019). Randomized trial of standard adjuvant chemotherapy regimens versus capecitabine in older women with early breast cancer: 10-year update of the CALGB 49907 trial. Journal of Clinical Oncology 37, 2338.

Natori, A., Ethier, J.-L., Amir, E., and Cescon, D. W. (2017). Capecitabine in early breast cancer: a meta-analysis of randomised controlled trials. European Journal of Cancer 77, 40-47.

O'Shaughnessy, J., Koeppen, H., Xiao, Y., Lackner, M. R., Paul, D., Stokoe, C., Pippen Jr, J., Krekow, L., Holmes, F. A., and Vukelja, S. (2015). Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clinical Cancer Research 21, 4305-4311.

Perou, C. M., Sørlie, T., Eisen, M. B., Van De Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., and Akslen, L. A. (2000). Molecular portraits of human breast tumours. nature 406, 747-752.

Pistelli, M., Merloni, F., Crocetti, S., Scortichini, L., Tassone, L., Cantini, L., Agostinelli, V., Bastianelli, L., Savini, A., and Berardi, R. (2021). Prognostic impact of Ki-67 change in locally advanced and early breast cancer after neoadjuvant chemotherapy: a single institution experience. Journal of oncology 2021, 1-7.

Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., and Wagner, P. (2005). Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical cancer research 11, 5678-5685.

Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., and Harbeck, N. (2020). Pembrolizumab for early triple-negative breast cancer. New England Journal of Medicine 382, 810-821.

Tao, M., Chen, S., Zhang, X., and Zhou, Q. (2017). Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Medicine 96.

Thall, P. F., Millikan, R. E., and Sung, H. G. (2000). Evaluating multiple treatment courses in clinical trials. Statistics in medicine 19, 1011-1028.

Von Minckwitz, G., Rezai, M., Fasching, P. A., Huober, J., Tesch, H., Bauerfeind, I., Hilfrich, J., Eidtmann, H., Gerber, B., and Hanusch, C. (2014). Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40—GeparQuattro). Annals of oncology 25, 81-89.

Wang, X., Wang, S.-S., Huang, H., Cai, L., Zhao, L., Peng, R.-J., Lin, Y., Tang, J., Zeng, J., and Zhang, L.-H. (2021). Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. Jama 325, 50-58.

Zhang, S., Wang, Z., Fan, S., Liu, T., Yoshida, S., Yang, S., Liu, L., Hou, W., Cao, L., and Wang, J. (2021). Capecitabine can induce T cell apoptosis: a potential immunosuppressive agent with anti-cancer effect. Frontiers in immunology 12, 3660.